2012 Biosimilars Compounding 
Pharmacy Times
JULY 26, 2025
Bristol Myers Squibb; 2012. Biomedicines. 2021;9(5):445. doi:10.3390/biomedicines9050445 Xarelto. Prescribing information. Janssen Pharmaceuticals, Inc; 2021. Accessed June 4, 2025. link] Eliquis. Prescribing information. Accessed June 4, 2025. link] Savaysa. Prescribing information. Daiichi Sankyo, Inc; 2015. Accessed June 4, 2025.
Pharmacy Times
JUNE 17, 2025
The National Institutes of Health reports that in 2012, $418 billion was wasted in the US due to suboptimal use of medications. Abstract Background Cost avoidance and waste reduction are defined as interventions made before the drug is dispensed to the patient that preclude an unnecessary prescription from being filled and sent to a patient.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 29, 2025
Specifically, psychology and psychiatry were among the disciplines where this increase was observed to be highest (P < 001). 2 Notably, in the field of biomedical research in autism spectrum disorder (ASD), negative results appear to be nearly absent, according to Joober et al. 2018;153(7):663-670. doi:10.1001/jamasurg.2018.0040
European Pharmaceutical Review
FEBRUARY 23, 2023
On the contrary, keeping stronger patents, eg, compound patents, in and opting less robust, second‑medical‑use patents out may help favourably shape the jurisprudence. Arrow declarations are useful for generics or biosimilars as they give commercial certainty that a product may be launched without the risk of a later infringement action.
European Pharmaceutical Review
JULY 4, 2024
2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).
FDA Law Blog: Biosimilars
AUGUST 10, 2023
Section 704(a)(4) was added to the FDCA by the Food and Drug Administration Safety and Innovation Action (FDASIA) in July 2012. Despite FDA having the authority to conduct paper inspections since the statutory provision was added to the FDCA by FDASIA in 2012, FDA did not issue a warning letter citing Section 704(a)(4) until January 2021.
PharmaShots
JUNE 28, 2023
Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. This list is not an exhaustive list.
Expert insights. Personalized for you.
Let's personalize your content